Company Intelligence
BeiGene
百济神州
No Known BCC Exposure
BeiGene is a drug innovator with its own manufacturing, not a contract manufacturer. It is not on the Section 1260H list. Its dual US-China corporate structure and NASDAQ listing provide structural transparency. No current BIOSECURE exposure.
Overview
BeiGene (百济神州) is a global biotechnology company focused on oncology. It is one of the few Chinese-founded biotechs to achieve significant commercial success in both China and the US, with its BTK inhibitor zanubrutinib (Brukinsa) generating $3.2B+ in 2025 revenue. BeiGene operates as a fully integrated biopharmaceutical company with its own commercial infrastructure in the US, Europe, and China.
Key Facts
- Zanubrutinib (Brukinsa) is the best-selling China-originated drug globally: $3.2B+ in 2025 revenue
- Dual-listed on NASDAQ and Hong Kong Stock Exchange
- Own US commercial operations — not dependent on licensing partners for US market access
- Pipeline includes 50+ clinical-stage candidates, primarily in hematologic and solid tumor oncology
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Novartis | 2021 | $650M upfront | Tislelizumab (PD-1) ex-China rights |
| Amgen | 2019 | $2.8B | Oncology portfolio collaboration |
Corporate Structure
Cayman Islands holding company (typical for Chinese biotech NASDAQ listings). Dual-listed: NASDAQ and HKEX. US operations run through BeiGene USA, Inc. China operations through BeiGene (Beijing) Co., Ltd. No VIE structure — uses direct WFOE model.